In a holiday-shortened week, shares of AbbVie Inc. NYSE: ABBV are down a little more than 3%. To put that in context, the drop in ABBV stock was more than that of biotech stocks such as Johnson & J...

AbbVie (ABBV) is seeking approval for Tepkinly in the EU as a monotherapy for the treatment of adult patients with relapsed/refractory follicular lymphoma after two or more prior therapies.

If you want a massive dividend snowball: Get the right combination of dividend yield and growth for maximum compounding effect. Dividend Aristocrats may not always be the best choice due to high va...

If approved, epcoritamab (TEPKINLY®) will become the first and only bispecific antibody conditionally approved as a monotherapy in the European Union to treat both relapsed or refractory (R/R) foll...

Following the label expansion, AbbVie's (ABBV) Epkinly is the first bispecific antibody approved to treat relapsed/refractory (R/R) follicular lymphoma and R/R diffuse large B-cell lymphoma.

U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for ABBV-951 based on observations from an inspection that did not involve ABBV-951 at one of AbbVie's third-party manu...

AbbVie is one of the world's largest pharmaceutical companies and one of the fastest dividend raisers in its industry. Shares of business development company Ares Capital offer a yield above 9% at ...

Recently, the biotech industry has taken a bit of a slower stance toward growth. With the Covid-19 pandemic in the rearview mirror, the focus of major pharmaceutical developers and biotech companie...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?

AbbVie's (ABBV) Skyrizi is now approved for four indications across immune-mediated inflammatory diseases.

Many dividend stocks have recently taken a back seat to growth stocks. However, dividend stocks offer several advantages to investors.

Approval supported by two Phase 3 clinical trials that evaluated SKYRIZI® for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance ...

AbbVie's weak stock price performance in the past quarter is in no way an indication of the progress it has made in recent months. Turnaround in revenue growth following Humira's patent expiration ...

AbbVie's strength lies in its ability to innovate. Visa's success is tied to an ongoing long-term trend.

NORTH CHICAGO, Ill. , June 14, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) has been notified that Tutanota LLC (Tutanota) has commenced an unsolicited "mini-tender" offer, dated May 28, 2024, to purch...